{"id":"da-1229","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1779710","moleculeType":"Small molecule","molecularWeight":"401.43"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By inhibiting DPP-4, DA-1229 prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), allowing these hormones to accumulate and enhance insulin secretion in response to meals while suppressing glucagon secretion. This mechanism improves glycemic control without causing hypoglycemia when used as monotherapy.","oneSentence":"DA-1229 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:30:48.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05143177","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)","status":"SUSPENDED","sponsor":"REDNVIA Co., Ltd.","startDate":"2022-06-27","conditions":"Calcific Aortic Valve Disease","enrollment":580},{"nctId":"NCT07297940","phase":"PHASE1","title":"Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State","status":"RECRUITING","sponsor":"Dong-A ST Co., Ltd.","startDate":"2025-12-14","conditions":"Healthy","enrollment":40},{"nctId":"NCT04055883","phase":"PHASE2","title":"Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-08-26","conditions":"Calcific Aortic Valve Disease","enrollment":228},{"nctId":"NCT02754219","phase":"PHASE1","title":"Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-09-22","conditions":"Liver Dysfunction","enrollment":24},{"nctId":"NCT02946541","phase":"PHASE3","title":"A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":160},{"nctId":"NCT02587975","phase":"PHASE4","title":"Effect of Evogliptin on Bone Metabolism in Human","status":"UNKNOWN","sponsor":"DongGuk University","startDate":"2016-06","conditions":"Diabetes Mellitus, Type 2, Osteoporosis","enrollment":20},{"nctId":"NCT02214693","phase":"PHASE1","title":"PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-07","conditions":"Renal Impairment","enrollment":30},{"nctId":"NCT02267902","phase":"PHASE1","title":"Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01941199","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT00961025","phase":"PHASE1","title":"A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects","status":"UNKNOWN","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2009-05","conditions":"Diabetes Mellitis Type 2","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Evogliptin"],"phase":"phase_2","status":"active","brandName":"DA-1229","genericName":"DA-1229","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-1229 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}